Does REGORAFENIB Cause Hepatocellular carcinoma? 470 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 470 reports of Hepatocellular carcinoma have been filed in association with REGORAFENIB (Stivarga). This represents 5.0% of all adverse event reports for REGORAFENIB.
470
Reports of Hepatocellular carcinoma with REGORAFENIB
5.0%
of all REGORAFENIB reports
99
Deaths
67
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From REGORAFENIB?
Of the 470 reports, 99 (21.1%) resulted in death, 67 (14.3%) required hospitalization, and 3 (0.6%) were considered life-threatening.
Is Hepatocellular carcinoma Listed in the Official Label?
Yes, Hepatocellular carcinoma is listed as a known adverse reaction in the official FDA drug label for REGORAFENIB.
What Other Side Effects Does REGORAFENIB Cause?
Off label use (1,906)
Fatigue (1,530)
Palmar-plantar erythrodysaesthesia syndrome (1,230)
Diarrhoea (1,221)
Decreased appetite (941)
Asthenia (825)
Death (813)
Dysphonia (702)
Nausea (688)
Pain in extremity (686)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
SOFOSBUVIR\VELPATASVIR (161)
Which REGORAFENIB Alternatives Have Lower Hepatocellular carcinoma Risk?
REGORAFENIB vs REGORAFENIB\REGORAFENIB
REGORAFENIB vs RELATLIMAB
REGORAFENIB vs RELPAX
REGORAFENIB vs RELUGOLIX
REGORAFENIB vs REMDESIVIR